In the first half of the year, we achieved very strong results, driven by high demand for our new medicines. I am very pleased with the expedited approvals health authorities granted for our new medicines. They represent important treatment options for patients fighting cancer.
At a glance
Roche has been building on its wide-ranging expertise and combined strengths in its Pharmaceuticals and Diagnostics divisions for the past 20 years. This has made the company a universally acknowledged pioneer and leader in this first wave of personalised healthcare. As part of these efforts, the company has developed targeted treatments, with additional regulatory approvals of new medicines granted in the first half of 2019.